Experimental diabetes drug Bydureon, developed by Eli Lilly and Amylin Pharmaceuticals, has been recommended for approval by the European Medicines Agency.

Bydureon is a longer-acting version of Byetta, another Lilly / Amylin collaboration, and only needs to be injected once a week to treat adults suffering from type-2 diabetes.

The two companies can now expect an endorsement from the European Commission within the coming months, but the drug faces further delays before entering the US market following a request for more data by regulators last October.

Bydureon and Byetta form part of a new class of diabetes medications that can lead to weight loss as well as the control of blood-sugar levels.